^
Association details:
| Biomarker: | EGFR exon 20 insertion |
|---|---|
| Cancer: | Thymic Carcinoma |
| Drug: | Focus V (anlotinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review
Published date:
09/30/2020
Excerpt:
...we report a case of an advanced thymic squamous cell carcinoma patient harboring EGFR exon 20 insertion...Also as an angiogenesis inhibitor, anlotinib had controlled his mediastinal mass...To date, over 23 months of progression‐free survival (PFS) and six years of overall survival (OS) have been achieved....this is the first report where anlotinib has been effective in controlling the progression of thymic carcinoma.
DOI:
10.1111/1759-7714.13658
